Publications by authors named "V Michelini"

Objectives: Describe an augmented intelligence approach to facilitate the update of evidence for associations in knowledge graphs.

Methods: New publications are filtered through multiple machine learning study classifiers, and filtered publications are combined with articles already included as evidence in the knowledge graph. The corpus is then subjected to named entity recognition, semantic dictionary mapping, term vector space modeling, pairwise similarity, and focal entity match to identify highly related publications.

View Article and Find Full Text PDF

The tumor genome of a patient with advanced pancreatic cancer was sequenced to identify potential therapeutic targetable mutations after standard of care failed to produce any significant overall response. Matched tumor-normal whole-genome sequencing revealed somatic mutations in , , , and a focal deletion of The variant was an in-frame deletion mutation (ΔN486_P490), which had been previously demonstrated to be a kinase-activating alteration in the BRAF kinase domain. Working with the Novartis patient assistance program allowed us to treat the patient with the BRAF inhibitor, dabrafenib.

View Article and Find Full Text PDF
Article Synopsis
  • The publication contained an error regarding the name of the fourteenth author.
  • The incorrect name was initially printed in the article.
  • The correct name has now been provided to clarify the mistake.
View Article and Find Full Text PDF
Article Synopsis
  • A clinical study was conducted in New York City with 30 glioblastoma patients to compare the effectiveness of whole genome sequencing (WGS) and RNA sequencing (RNA-seq) against targeted panel sequencing in identifying treatment options.
  • WGS/RNA-seq uncovered significantly more actionable clinical results—90% of the time—with an average of 16 times more unique variants identified, leading to 84 calls for actionable treatments that targeted panels missed.
  • The study found good agreement between manual and automated variant identification, showing that clinicians modified treatment plans based on this data in 10% of cases, marking a significant advancement in cancer treatment analysis.
View Article and Find Full Text PDF

Oncologists increasingly rely on clinical genome sequencing to pursue effective, molecularly targeted therapies. This study assesses the validity and utility of the artificial intelligence Watson for Genomics (WfG) for analyzing clinical sequencing results. This study identified patients with solid tumors who participated in in-house genome sequencing projects at a single cancer specialty hospital between April 2013 and October 2016.

View Article and Find Full Text PDF